cResponse™ Research and Evidence
The cResponse™ platform:
A phase 2 clinical trial of cResponse, a functional assay for cancer precision medicine – Poster presented at the 2023 Molecular Analysis for Precision Oncology Congress (MAP)
Frontiers in Medicine
A clinical evaluation of the cResponse system to predict patient response to cancer therapy – Published in “Frontiers in Medicine”, September 2023
A phase 2 clinical trial of cResponse, a functional assay for cancer precision medicine – Poster presented at the American Association for Cancer Research (AACR) Conference, April 2023.
Using the cResponse Technology to Evaluate a T-Cell Bispecific CEACAM5 Therapy – Poster presented at the 2022 ESMO Immuno-Oncology Congress
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer
Curesponse Related Research
Ben-Hamo R., Berger AJ., Gavert N., et al. Predicting and affecting response to cancer therapy based on pathway-level biomarkers. Nat Commun. 2020 Jul 3;11(1):3296.
Grinshpun A, Gavert N, Granit RZ., et al. Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy. Cancer Biol Ther. 2018 Aug 3;19(8):645-648.
Geller LT., Barzily-Rokni M., Danino T., et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
Straussman R., Morikawa T., Kevin Shee K., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26; 487(7408): 500–504.
Comparing intraperitoneal and intravenous personalized ErbB2CAR-T for the treatment of epithelial ovarian cancer. Biomedicines. 2022 Sep 7;10(9):2216.
Narunsky-Haziza, Straussman et al., Cell 185, 3789–3806 ,September 2022. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions.
Stossel, Berger, Golan et al., Cancer Discovery 2023;13:1–18. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting.